Association between gut microbiota, plasma metabolites, and ovarian cancer: A Mendelian randomization study

Yu Wang,Shanxiang Gao,Yangyu Liu,Yongai Li,Hui Yao,Yan Han,Xinyue Liu

DOI: https://doi.org/10.1097/md.0000000000040479

IF: 1.6

2024-11-13

Medicine

Abstract:Ovarian cancer (OC) is among the most prevalent malignant tumors in the field of gynecology, and it is the primary cause of death among cancers affecting the female reproductive system. The prognosis for OC is unfavorable, with a 5-year survival rate of approximately 47%. [ 1 ] In recent years, the potential connection between the microbiota and the development of cancer has emerged as a topic of increasing interest and debate. Among the different regions of the body, the human gut microbiota (GM) is particularly noteworthy as a vital constituent of the human microbiome, displaying the greatest bacterial richness and diversity. [ 2 ] Dysbiosis in the GM seems to contribute to the development of cancer by disrupting the physiological balance of intestinal epithelial cells. A representative microbiota has been identified in women with OC: a unique set of viruses, bacteria, fungi, and parasites have been identified in a pan-pathogen array. [ 3 ] Substantial efforts have been devoted to elucidating the pathophysiological mechanisms underlying carcinogenesis driven by microbial factors. Well-established factors, such as the tumor-promoting microenvironment, epithelial barrier dysfunction, altered metabolic processes, and immune dysregulation, have been linked to specific bacteria within dysbiotic microbial communities. [ 4 ] Research has demonstrated that an imbalance in the GM can impact the levels of human metabolites, thereby influencing tumor occurrence and development. [ 5–10 ] Given that patients diagnosed with OC frequently experience gastrointestinal symptoms like abdominal pain, bloating, indigestion, constipation, and early satiety, exploring the potential link between alterations in the GM and OC carcinogenesis is indeed intriguing. Nevertheless, the research on the complex interactions between GM, associated metabolites, and OC has a rather limited scope. Therefore, there is a need for comprehensive exploration to understand the complex mechanisms by which changes in GM and related metabolites impact OC development and treatment pathways, as well as to identify potential metabolites that can be utilized for early diagnosis and clinical therapeutic targets.

medicine, general & internal